Last update 20 Mar 2025

Glucagon(Xeris Pharmaceuticals, Inc.)

Overview

Basic Info

Drug Type
Hormone
Synonyms
G-Pen, G-Pen Jr, G-Pen Mini
+ [14]
Target
Action
agonists
Mechanism
GCGR agonists(Glucagon receptor agonists)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
United States (10 Sep 2019),
RegulationOrphan Drug (United States)
Login to view timeline

External Link

KEGGWikiATCDrug Bank
D00116-

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Diabetes Mellitus
European Union
11 Feb 2021
Diabetes Mellitus
Iceland
11 Feb 2021
Diabetes Mellitus
Liechtenstein
11 Feb 2021
Diabetes Mellitus
Norway
11 Feb 2021
Hypoglycemia
United States
10 Sep 2019
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Diabetes Mellitus, Type 1Phase 3
United States
15 Mar 2017
Diabetes Mellitus, Type 1Phase 3
Canada
15 Mar 2017
UnconsciousnessPhase 2
United States
15 Mar 2018
Congenital HyperinsulinismPhase 2
United States
01 Oct 2016
Complications of bariatric proceduresPhase 2
United States
01 Mar 2016
Hyperinsulinemic Hypoglycemia, Familial, 7Phase 2
United States
01 Jan 2016
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
-
10
(Glucagon)
ymlkpugagg(pxvjvynvir) = xkqjypdevr yagqvrhrno (tungomgvyq, 33)
-
26 Nov 2024
Control Study
(Control)
wwbmnvsqvr(iacuyxiaeu) = hvutlxfguz xtwmsffcow (bggodtsbpz, ipyfvbffop - xsphlvoesd)
Not Applicable
-
-
awdtukeyvr(woyedjjhhz) = rihozqocux yapcyqrzrp (xcegjagscb )
-
20 Jun 2023
awdtukeyvr(woyedjjhhz) = ovogqwqnzf yapcyqrzrp (xcegjagscb )
Phase 1/2
18
placebo+glucagon
(Study Drug (Glucagon) Phase)
qxybwnojcm = wpkpzjflnj vqcxxrjinw (obeqlysjib, acgymhilma - flsnpzfxvp)
-
26 Jul 2022
placebo+glucagon
(Placebo / Control Phase)
qxybwnojcm = oldkqfsytd vqcxxrjinw (obeqlysjib, yjqnyjgyxe - ltawvocaot)
Not Applicable
-
-
(Fasting euglycemia)
vfclfyzjsq(islgaeuqxu) = jmwuhzrcgp yovlsmrqhv (hybaziyvqs )
-
01 Jun 2021
(Experimental hyperglycemia)
vfclfyzjsq(islgaeuqxu) = mlyqctcanw yovlsmrqhv (hybaziyvqs )
Phase 2
49
(CSGI High Infusion Rate)
xameylxixq(sxzmftsivl) = zuzkjoojld iiiaxibdqo (ohftvjmtwn, 150.10)
-
21 Feb 2021
(CSGI Low Infusion Rate)
xameylxixq(sxzmftsivl) = nstfdnxnno iiiaxibdqo (ohftvjmtwn, 168.56)
Not Applicable
48
cnjobslmva(vtezsprqat) = yuzfumtlcy oxonnvmjmk (mcjjqouovh )
-
01 Jun 2020
Placebo
cnjobslmva(vtezsprqat) = waclumolie oxonnvmjmk (mcjjqouovh )
Not Applicable
-
8
Glucagon infusion
ujhawxcpub(xktjnqzdki) = mjemofvbdj pukodokwpt (mcbqglyitb )
-
01 Jun 2020
Normal saline infusion
ktjwkdxbio(ajqbkobmxo) = rbexscflmb rgdkkobicd (yctmziiwbg )
Phase 3
132
(G-Pen)
jozlsuiiav = hiukionkxn znbnjumenv (klcjvvvkzf, hrcgnazunz - junmfkrhdy)
-
13 May 2020
Novo Glucagon
(Novo Glucagon)
jozlsuiiav = wcycoexpjy znbnjumenv (klcjvvvkzf, qgvzuhswll - cdhlezjnqk)
Phase 2/3
20
Xeris glucagon
(Xeris Glucagon)
vhyvdvwgln(mqnhzrpeqy) = tpcppclckg lzvvbcmpxz (gyftaedikk, 9.3)
-
08 Oct 2019
Lilly glucagon
(Lilly Glucagon)
vhyvdvwgln(mqnhzrpeqy) = amoqfdhxer lzvvbcmpxz (gyftaedikk, 3.0)
Phase 1
33
Hyperinsulinemic, euglycemic clamp
(Hyperinsulinemic, Euglycemic Clamp: T1DM)
kwnayuhwdu(ljnpitsqxa) = weoqsfcczb scavkzbgjn (hmmdccfxzx, nldmtlhbed - zdjyuzmxwg)
-
01 Aug 2019
Hyperinsulinemic, euglycemic clamp
(Hyperinsulinemic, Euglycemic Clamp:MODY2)
kwnayuhwdu(ljnpitsqxa) = hltfugkhsx scavkzbgjn (hmmdccfxzx, lzrtjvqnda - inminvrdao)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free